Bissonnette is a board-certified dermatologist and is also chief executive officer and medical director of Innovaderm Research Inc., a contract research organization that specializes in conducting clinical studies in dermatology.
(Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD) were presented at the European Academy of Dermatology and Venereology (EADV) Congress by Robert Bissonnette, M.D., FRCPC. 30, 2021 (GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. Continued improvement observed 2 weeks after end of treatment on multiple endpoints.Benefit demonstrated in all key exploratory efficacy endpoints - EASI, EASI-50, EASI-75, EASI-90, vIGA, BSA and pruritus NRS-3 and 4 - with once-daily, oral treatment with RPT193.
0 kommentar(er)
